Drug news
Merck Inc., takes a $2.9 billion charge on uprifsobuvir (MK 3682) as the Hepatitis C market diminishes.
Merck Inc, is taking a $2.9 billion charge on uprifsobuvir (MK 3682) which it acquired with Idenix Pharma and which is in early trials. The potential Hepatitis C market is now diminishing with the treatable population reducing as Harvoni and Sovaldi, from Gilead, have turned the disease into a treatable one. Mercks estimates for uprifsobuvir were down to $240 million and the diminishing market was reflected in sales of Sovaldi and Harvoni for year ended 2016 when they fell 32% and 34% respectively year over year.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
4 mins